theMednetRegister

Rheumatology

COVID-19   

Questions discussed in this category

What is your preferred first-line treatment for chronic fatigue in patients with long COVID-19?
7 Answers available
What isolation policies are Rheumatology offices employing for both staff and patients diagnosed with COVID-19 given the new CDC guidelines?
CDC Healthcare Guidance CDC Isolation and Work Restriction Guidance CDC Immunocompromised Guidance
1 Answer available
Is rituximab for refractory ITP contraindicated in the setting of an active COVID infection, particularly in a patient with asymptomatic COVID?
2 Answers available
How do you approach Covid vaccine counseling in patients with rheumatic disease and history of pericarditis/serositis?
1 Answer available
What is the difference between Multisystem Inflammatory Syndrome in Adults (MIS-A) and MAS/HLH?
1 Answer available
Do you recommend using IL-1/IL-6 inhibitors in COVID-19 multisystem inflammatory syndrome in adults (MIS-A)?
1 Answer available
Do you recommend routine use of Evusheld for pre-exposure prophylaxis for patients on immunosuppression?
Does treatment with B-cell depletion and/or negative anti-spike antibody status despite COVID mRNA vaccination influence your decision?
1 Answer available
Should we recommend the COVID-19 booster vaccine to patients who had a DVT or any other complications such as hemolytic anemia or thrombocytopenia from prior vaccine doses?
2 Answers available
Is there a role for antibody testing to confirm vaccine response for patients on rituximab after COVID-19 vaccination?
1 Answer available
How will you use REGEN-COV (casirivimab/imdevimab-monoclonal antibody treatment recently approved under EUA as post-exposure prophylaxis for Covid) in rheumatic patients on immunosuppressive therapy?
Would you consider this for patients on B-cell depleting therapies or more broadly for other immunosuppressive agents?
2 Answers available
What are your recommendations regarding methotrexate usage in patients with persistent chest CT changes post COVID pneumonia?
Would you have a different opinion based on whether it is a new therapy or an existing and previously well-tolerated therapy for the patient?
2 Answers available
Do you recommend COVID vaccination in patients with antiphospholipid antibody positivity or other prothrombotic states not on anti-coagulation?
1 Answer available
How are you timing the third dose of the COVID-19 mRNA vaccine in patients on rituximab?
1 Answer available
In which patients with autoimmune or inflammatory conditions are you recommending a 3rd dose of the mRNA COVID vaccine?
2 Answers available
How would you advise patients with known stable autoimmune thrombocytopenia regarding the Ad26.COV2.S (Johnson & Johnson/Janssen) vaccine?
1 Answer available
How do you advise patients who had autoimmune diseases "triggered" by COVID infections on getting COVID vaccination?
E.g., inflammatory polyarthritis or inflammatory myopathy with onset within 2 weeks of documented COVID infection
1 Answer available
Are there particular concerns related to the use of B-cell depletion therapies such as rituximab for rheumatic disease during the COVID-19 pandemic?
1 Answer available
When would you recommended restarting biologic medications in an active RA patient after treatment with monoclonal antibodies, convalescent plasma or antiviral medications for a COVID-19 infection?
1 Answer available
Are you recommending tocilizumab for any COVID-19 patients?
Current guidelines do not support its use, but the EMPACTA trial suggests it may be effective in a subpopulation of patients.
1 Answer available
Are you recommending the mRNA COVID-19 vaccines to your patients with immune mediated inflammatory diseases?
5 Answers available
Is there an increased risk of COVID-19 in patients on immunosuppressants?
1 Answer available
In light of promising results of hydroxychloroquine in COVID-19, should we consider using it prophylactically in cancer patients, especially if immunocompromised?
Acknowledging that there is no time for good trials yet in this setting
1 Answer available
Is your approach to managing immune related adverse events altered at all in light of COVID-19?
2 Answers available


Papers discussed in this category

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-06-10
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.
Lancet Oncol., 2020 Mar 03
Risk of COVID-19 for patients with cancer.
Lancet, 2020 Feb 07
Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury.
N Engl J Med, 2020 Apr 29
Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series from New York.
Rheumatol Int, 2020 Sep 18
High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study.
N Engl J Med, 2020 Dec 10
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19.
N Engl J Med, 2020 Dec 17
Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia.
Lancet Rheumatol, 2021 Apr 06
Incident systemic rheumatic disease following COVID-19.
N Engl J Med, 2020 Nov 20
Covid-19-Associated Myopathy Caused by Type I Interferonopathy.
Blood,
Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance.
Arthritis Rheumatol, 2021 May 24
American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 1.
N Engl J Med, 2021 Aug 04
Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19.
Semin Hematol,
Epidemiology and risk factors for venous thrombosis.
BMJ Open, 2019 May 05
Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts.
Rheumatol Int, 2021 Jan 29
Does methotrexate cause progressive fibrotic interstitial lung disease? A systematic review.
Thromb Res, 2021 Jun 25
Absence of hypercoagulability after nCoV-19 vaccination: An observational pilot study.
ACR Open Rheumatol, 2021 Aug 25
Performance of Cytokine Storm Syndrome Scoring Systems in Pediatric COVID-19 and Multisystem Inflammatory Syndrome in Children.
Medical sciences (Basel, Switzerland), 2018-09-21
Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization.
The Journal of clinical investigation, 2021 Dec 15
The intersection of COVID-19 and autoimmunity.
Molecular systems biology, 2023 Mar 15
A methylation clock model of mild SARS-CoV-2 infection provides insight into immune dysregulation.
BMJ open, 2024 May 13
Low-dose naltrexone for post-COVID fatigue syndrome: a study protocol for a double-blind, randomised trial in British Columbia.

Related Topics in Rheumatology

Copyright © 2024 theMednet
All Rights Reserved.